YOLFTbeta
17

AbClon Inc

174900 · KQ · Healthcare / Biotechnology

22,950.00KRW+1100.00 (+5.03%)

Price History

Full chart

Market Stats

Previous Close21,850.00
Open21,950.00
Day Range21,750.00 – 25,350.00
52-Week Range16,250.00 – 95,800.00
Volume199.75K
Market Cap561.65B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.81
50-Day Avg23,772.40
200-Day Avg42,404.00

About

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOKim Kyu-Tae
  • Employees0
  • Headquarters1401 285, Digital-ro, Seoul, South Korea, 08381, Korea
  • Websitehttps://www.abclon.com

Leadership

  • Kim Kyu-TaeChief Scientific Officer and Member of Scientific Advisory Board
  • Dou Xian JinManaging Director
  • Mr. Jin-ha HwangBusiness Development Team Manager · b. 1976

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.95B3.12B3.53B3.92B14.38B2.77B3.02B3.41B2.88B2.34B4.71B
Growth (%)-+60.18%+13.21%+10.99%+266.64%-80.72%+8.91%+12.87%-15.54%-18.67%+101.47%
Cost of Revenue1.50B1.34B1.52B1.65B1.38B1.56B1.40B1.03B807.31M1.26B3.57B
Gross Profit451.07M1.78B2.01B2.27B13.00B1.21B1.62B2.38B2.07B1.08B1.14B
Gross Margin23.15%56.91%56.89%57.80%90.43%43.78%53.62%69.82%71.94%46.02%24.19%
Operating Expense3.54B3.38B3.55B4.22B8.72B7.78B11.85B11.13B13.88B16.67B18.78B
Operating Income-3.09B-1.61B-1.54B-1.96B4.28B-6.57B-10.23B-8.75B-11.81B-15.59B-17.64B
Operating Margin-158.48%-51.47%-43.74%-49.88%29.80%-237.13%-338.93%-256.86%-410.45%-666.24%-374.11%
EBITDA--------8.33B-9.86B-13.81B-16.34B
EBITDA Margin--------244.61%-342.67%-590.25%-346.70%
Net Income-9.84B-1.60B-1.48B-842.70M2.57B-6.44B-10.24B-9.25B-12.90B-16.30B-17.91B
Net Income Margin-505.24%-51.17%-41.97%-21.49%17.85%-232.57%-339.22%-271.66%-448.53%-696.70%-379.86%
R&D1.85B1.99B1.72B2.37B3.88B5.86B9.63B8.69B10.73B13.39B14.43B
R&D as % of Total Revenue95.05%63.84%48.60%60.39%26.98%211.43%318.94%255.19%373.09%572.42%306.13%
Interest Expense0000151.76M189.03M178.74M489.59M1.35B900.06M438.68M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.06%6.82%5.92%14.37%46.94%38.47%9.31%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.17B16.01B20.87B28.70B46.97B40.13B29.83B54.06B45.42B48.18B70.75B
Total Liabilities2.86B4.03B3.47B10.00B11.59B10.80B10.47B17.46B18.19B18.78B10.31B
Total Equity13.31B11.98B17.39B18.70B35.38B29.33B19.36B36.60B27.23B29.41B60.44B
Cash2.16B2.14B3.83B6.85B3.44B1.54B765.54M5.30B12.26B18.86B39.01B
Total Debt2.00B2.00B--5.01B5.09B-----
Net Debt-----5.46B6.23B6.27B269.26M--

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.20B-204.92M-1.11B3.71B-449.88M-5.65B-8.64B-7.49B-9.48B-14.39B-13.83B
Investing Cash Flow-10.08B257.81M-3.87B-2.89B-22.14B3.75B7.99B-9.46B13.55B2.07B-
Financing Cash Flow14.10B6.69B6.69B2.29B19.07B-8.96M-116.81M21.49B2.89B18.84B-
Capital Expenditure3.42B242.19M63.67M2.36B10.56B3.44B505.41M75.63M49.84M167.49M617.64M
Free Cash Flow-----16.15B-9.09B-9.17B-7.58B-9.53B-14.56B-14.45B
FCF to OCF----3589.63%160.92%106.05%101.20%100.53%101.16%104.47%

Earnings

Report DateSep 30, 2017Mar 13, 2018May 13, 2018Aug 14, 2018Nov 12, 2018Mar 19, 2019May 12, 2019Aug 13, 2019Nov 13, 2019Feb 9, 2020May 14, 2020Aug 13, 2020Nov 13, 2020Feb 4, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------
EPS Actual-49.05-48.41-1.03-42.28-58.8140.50392.50-103.03-45.89-64.50-126.78-144.58-81.00-120.04-176.04-296.04-117.25-141.84-169.04-160.59-168.84-108.46-145.27-98.62-275.42-321.51-358.03-235.52-198.33-187.09-339.98-189.34-184.46-264.89-145.05-309.20
Surprise------------------------------------
Timing-After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market-Pre-market----------------------

Key Statistics & Ratios

Market Cap561.65B
Enterprise Value362.42B
Trailing P/E0.00
Forward P/E0.00
Price / Sales105.82
Price / Book7.41
Revenue (TTM)5.31B
Gross Profit (TTM)645.83M
EBITDA-17.25B
Profit Margin0.00%
Operating Margin-371.39%
Return on Equity-40.78%
Return on Assets-21.37%
Shares Outstanding19.95M
Shares Float15.94M
Beta0.81
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jul 16, 20202:1